
How a framework of living cells can inform drug discovery
DDW Editor Reece Armstrong speaks to Yerem Yeghiazarians, CEO and Co-Founder of Soley Therapeutics, about the limitations of current assays and how the company’s live cell approach can improve drug discovery. RA: What are the current limitations of static assays and single endpoints in assessing how cells respond to drugs? YY: Most conventional assays provide a… Read More

